{"chain_id": "chain_000000", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5948914", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5948914, is the following pharmacogenomic claim supported or contradicted: Genotypes GT + TT are not associated with overall survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The paper does not mention any significant association between the GT + TT genotypes and overall survival when treated with gemcitabine in people with Non-Small-Cell Lung Carcinoma, as compared to the GG genotype.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2231142 and gemcitabine in Disease:Non-Small Cell Lung Carcinoma (PMCID PMC5948914), what p-value was reported for this association?", "answer": "= 0.080", "response": "The reported p-value for the association of rs2231142 (ABCG2 Q141K) with progression-free survival in Non-Small Cell Lung Carcinoma patients treated with gemcitabine was adjusted *P* = 0.007.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True.", "correct": false}]}
{"chain_id": "chain_000001", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC11732454", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11732454, is the following pharmacogenomic claim supported or contradicted: HLA-A *31:03 is associated with decreased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of HLA-A*31:03 and carbamazepine, lamotrigine, phenytoin in Toxicity (PMCID PMC11732454), what confidence interval was reported?", "answer": "0.13\u20130.27", "response": "The confidence interval reported for HLA-A*31:03 in relation to Stevens-Johnson Syndrome was 0.13\u20130.27. However, the study does not specifically mention a confidence interval for HLA-A*31:03 in relation to carbamazepine, lamotrigine, or phenytoin in the context of Toxicity.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000002", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4640545", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4640545, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2298771 and carbamazepine in Disease:Epilepsy (PMCID PMC4640545), what p-value was reported for this association?", "answer": "> 0.05", "response": "The study reported no significant association between rs2298771 (SCN1A c.3184A>G) and carbamazepine metabolism, and thus no specific p-value for this association was highlighted in the results.", "correct": true}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000003", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4177494", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4177494, is the following pharmacogenomic claim supported or contradicted: Genotypes GG + GT is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs8099917 and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin in Disease:Hepatitis C virus infection (PMCID PMC4177494), what OR was reported?", "answer": "7.9", "response": "The reported odds ratio (OR) for the rs8099917 G allele as a predictor of null-response was 7.9, with a 95% confidence interval of 1.99-31.18.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000004", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC7351433", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC7351433, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The paper reports that the MTHFR rs1801133 TT genotype is associated with higher plasma methotrexate levels compared to the CC genotype, indicating that the alleles do have an association with methotrexate concentrations.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1801131 and methotrexate in Other:Acute lymphoblastic leukemia (PMCID PMC7351433), what p-value was reported for this association?", "answer": "> 0.05", "response": "The study reported a p-value of <0.05 for the association between the MTHFR rs1801131 AC genotype and decreased hepatic toxicity in the context of methotrexate treatment in acute lymphoblastic leukemia.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True", "correct": false}]}
{"chain_id": "chain_000005", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3909071", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3909071, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs13242038 and heroin in Other (PMCID PMC3909071)?", "answer": 619, "response": "619 controls were included in the study of rs13242038 and heroin.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000006", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5519037", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5519037, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs776746 and everolimus in Disease:Breast Neoplasms (PMCID PMC5519037), what p-value was reported for this association?", "answer": "> 0.05", "response": "The study reported no significant differences for the association between rs776746 and everolimus concentrations, but it did not specify a p-value for this association.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000007", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5207665", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5207665, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with response to bevacizumab in women with Breast Neoplasms as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not provide specific information about an \"Allele A\" or \"Allele G\" in relation to response to bevacizumab in women with breast neoplasms. The study discusses various SNPs and their associations with pathologic complete response (pCR) to bevacizumab, but it does not specify alleles in the manner described in the claim. Therefore, based on the information provided in the paper, the claim cannot be directly evaluated as supported or contradicted. However, if we consider the general findings, the paper does identify specific SNPs associated with response, suggesting that certain alleles do have associations. Without specific reference to \"Allele A\" and \"Allele G,\" the claim remains unaddressed. Thus, the claim is neither supported nor contradicted by the paper.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs17577 and bevacizumab in Disease:Breast Neoplasms (PMCID PMC5207665)?", "answer": 33, "response": "The paper does not mention rs17577 specifically in relation to bevacizumab and breast neoplasms. Therefore, there is no information provided about the number of controls included in the study for rs17577.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "False.", "correct": false}]}
{"chain_id": "chain_000008", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC1689719", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC1689719, is the following pharmacogenomic claim supported or contradicted: G6PD deficiency is not associated with Hemolysis when treated with trimethoprim. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not specifically mention trimethoprim in relation to G6PD deficiency and hemolysis. It discusses drugs like primaquine, nitrofurantoin, aspirin, and sulphamethoxazole. Since trimethoprim is not addressed, the paper neither supports nor contradicts the claim. However, based on the information provided, the claim is not directly supported by this paper.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of G6PD deficiency and trimethoprim in Toxicity (PMCID PMC1689719)?", "answer": 8, "response": "The paper does not provide specific information on the number of cases studied for G6PD deficiency and trimethoprim toxicity. Trimethoprim is not mentioned in the context of this study.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000009", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2850440", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2850440, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with increased risk of Crohn Disease. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2542151 (PMCID PMC2850440), what OR was reported?", "answer": "1.0834", "response": "The reported odds ratio (OR) for rs2542151 in the study was 1.0834 for the non-Hispanic European ancestry group and 1.0446 for the non-Hispanic European + unknown ancestry group.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000010", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5331771", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5331771, is the following pharmacogenomic claim supported or contradicted: Genotypes AG + GG are associated with increased platelet reactivity when treated with aspirin and clopidogrel as compared to genotype AA. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not specifically mention genotypes AG, GG, or AA in relation to increased platelet reactivity when treated with aspirin and clopidogrel. The study focuses on the effects of specific polymorphisms such as CYP2C19*2, CYP2C19*17, and P2Y12 on platelet reactivity. Therefore, the claim regarding genotypes AG + GG versus AA is not addressed in this paper. Thus, the claim is neither supported nor contradicted by the findings of this study.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2046934 and aspirin, clopidogrel in Efficacy (PMCID PMC5331771), what confidence interval was reported?", "answer": "1.64\u20133.53", "response": "The study does not report a specific confidence interval for the association of rs2046934 with aspirin and clopidogrel efficacy. The paper discusses the association of P2Y12 polymorphisms, including rs2046934, with clinical outcomes and platelet reactivity, but it does not provide a specific confidence interval for this SNP in relation to aspirin and clopidogrel efficacy.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "The paper does not provide a specific confidence interval for the odds ratio (OR) related to rs2046934 and aspirin, clopidogrel efficacy. Therefore, it is not possible to determine whether the confidence interval for the OR excludes the null value of 1.0 based on the information provided in the paper. Thus, the answer is false.", "correct": false}]}
{"chain_id": "chain_000011", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC6021962", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC6021962, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not provide specific information about an allele T versus allele C comparison in relation to tacrolimus trough concentrations. The study focused on validating 44 SNPs associated with tacrolimus trough concentrations, and only variants in CYP3A4 and CYP3A5 were significantly associated. Without specific information on the alleles T and C in the context of this study, the claim cannot be directly evaluated as supported or contradicted based on the provided paper. Therefore, the claim is neither supported nor contradicted by the paper.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs10264272 and tacrolimus in Disease:Kidney Transplantation, Disease:Transplantation (PMCID PMC6021962), what p-value was reported for this association?", "answer": "= 0.269", "response": "The p-value reported for the association of rs10264272 with tacrolimus in the context of Kidney Transplantation and Transplantation was 0.269.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000012", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4039076", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4039076, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased minimal residual disease when treated with asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not provide specific information about the association of Allele A with increased minimal residual disease when treated with the mentioned drugs in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C. Therefore, the claim is neither supported nor contradicted by the findings of this paper.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3824662 and asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine, vincristine in Disease:Acute lymphoblastic leukemia (PMCID PMC4039076), what p-value was reported for this association?", "answer": "= 0.039", "response": "The paper does not report a specific p-value for the association of rs3824662 with the treatment involving asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine, and vincristine in Acute Lymphoblastic Leukemia. The study primarily focuses on the association of rs3824662 with Ph-like ALL and its related genetic and clinical outcomes.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "The paper reports a p-value of 2.17\u00d710^-14 for the association of rs3824662 with Ph-like ALL versus non-ALL, and a p-value of 1.05\u00d710^-8 for Ph-like ALL versus non-Ph-like ALL. Both p-values are well below the alpha level of 0.05, indicating that the findings are statistically significant. Therefore, the answer is true.", "correct": true}]}
{"chain_id": "chain_000013", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC8602039", "num_turns": 2, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC8602039, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC8602039, rs74569896 is associated with Efficacy, Toxicity, Metabolism/PK outcomes for aspirin, clopidogrel. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "The claim is not_reported. The paper discusses the association of rs74569896 with major adverse cardiovascular events (MACE) in patients treated with clopidogrel and aspirin, but it does not specifically address the association of rs74569896 with efficacy, toxicity, or metabolism/pharmacokinetic (PK) outcomes for aspirin or clopidogrel.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC8602039 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMCID PMC8602039 reports quantitative statistics for the association of rs74569896 with major adverse cardiovascular events (MACE). In the discovery stage, the odds ratio (OR) is 2.87 with a 95% confidence interval (CI) of 1.51\u20135.45 and a p-value of 3.87 \u00d7 10^\u22123. In the replication stage, the hazard ratio (HR) is 1.90 with a 95% CI of 1.39\u20132.61 and a p-value of 5.91 \u00d7 10^\u22125. The meta-analysis p-value is 1.31 \u00d7 10^\u22126.", "correct": false}]}
{"chain_id": "chain_000014", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5538123", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5538123, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The paper found that allele A of the SNP rs6706232 in the UGT1A3 gene was associated with a better response to risperidone treatment in the Chinese Han population, as it accounted for a higher proportion in good responders compared to poor responders.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs6313 and risperidone in Other:Schizophrenia (PMCID PMC5538123), what p-value was reported for this association?", "answer": "= 1", "response": "The p-value reported for the association between rs6313 and risperidone response in schizophrenia was 0.447.", "correct": false}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000015", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3773276", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3773276, is the following pharmacogenomic claim supported or contradicted: CYP2C19 *17 is not associated with post-treatment ADP-stimulated platelet aggregation when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2C19*17 and clopidogrel in Efficacy (PMCID PMC3773276), what p-value was reported for this association?", "answer": "= 0.01", "response": "The p-value reported for the association of CYP2C19*17 with post-treatment ADP-stimulated platelet aggregation, after adjusting for the CYP2C19*2 variant, was 0.69.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "False.", "correct": false}]}
{"chain_id": "chain_000016", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4864175", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4864175, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with risk of cognitive dysfunction due to opioids in people with Neoplasms as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs2160652 and opioids in Disease:Neoplasms (PMCID PMC4864175)?", "answer": 98, "response": "The study included 202 cases in the discovery sample and 98 cases in the validation sample for the analysis of rs2160652 and opioids in patients with neoplasms.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000017", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4519434", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4519434, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3778151 and heroin in Toxicity (PMCID PMC4519434), what p-value was reported for this association?", "answer": "= 3E-3", "response": "The p-value reported for the association of rs3778151 with heroin addiction in the study was 2.4\u00d710^-7.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000018", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5908896", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5908896, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with severity of Neutropenia when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The paper does not report a significant association between the STAT-3 rs1053004 polymorphism (allele C) and the severity of neutropenia in patients treated with FOLFIRI (fluorouracil, irinotecan, and leucovorin) for colorectal cancer. The focus of the paper is on the association of this polymorphism with gastrointestinal toxicity, not neutropenia.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2972164 and fluorouracil, irinotecan, leucovorin in Disease:Colorectal Neoplasms (PMCID PMC5908896), what OR was reported?", "answer": "1.34", "response": "For the study of rs2972164 in the context of treatment with fluorouracil, irinotecan, and leucovorin in colorectal neoplasms, the reported odds ratio (OR) for grade 3\u20134 neutropenia in the discovery cohort was 0.36 with a 95% confidence interval (CI) of 0.16\u20130.82.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True.", "correct": false}]}
{"chain_id": "chain_000019", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2761685", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2761685, is the following pharmacogenomic claim supported or contradicted: Genotype GG is associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1051375 and verapamil in Disease:Coronary Artery Disease (PMCID PMC2761685), what confidence interval was reported?", "answer": "1.67\u201312.67", "response": "The confidence interval reported for the rs1051375 G/G genotype associated with an increased risk of the primary outcome when treated with verapamil compared to atenolol was 95% CI 1.67-12.67.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000020", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2966859", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2966859, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs9394992 and gemcitabine in Disease:Pancreatic Neoplasms (PMCID PMC2966859), what HR was reported?", "answer": "1.08", "response": "The reported hazard ratio (HR) for rs9394992 in the study was 1.08 (95% CI: 0.74-1.57).", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the HR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000021", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3619396", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3619396, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with risk of Hypersensitivity when treated with sulfamethoxazole / trimethoprim in people with Infection. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs77005399 and sulfamethoxazole / trimethoprim in Disease:Infectious disease (PMCID PMC3619396)?", "answer": 99, "response": "Ninety-nine cases were included in the study of rs77005399 and sulfamethoxazole/trimethoprim in infectious disease.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000022", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3798385", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3798385, is the following pharmacogenomic claim supported or contradicted: Genotype CG is associated with increased risk of Neurotoxicity Syndromes when treated with carboplatin, docetaxel and paclitaxel in women with Ovarian Neoplasms as compared to genotypes CC + GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs139887 and carboplatin, docetaxel, paclitaxel in Disease:Ovarian Neoplasms (PMCID PMC3798385), what OR was reported?", "answer": "1.77", "response": "The reported odds ratio (OR) for rs139887 in the study was 1.77.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000023", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC9031832", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC9031832, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity and Fetal Alcohol Syndrome as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs1800497 and methylphenidate in Other:Attention Deficit Disorder with Hyperactivity, Other:Fetal Alcohol Syndrome (PMCID PMC9031832)?", "answer": 114, "response": "The study included 114 cases of children with ADHD symptoms, which were analyzed for the rs1800497 polymorphism in relation to methylphenidate treatment.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000024", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC9957000", "num_turns": 2, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC9957000, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC9957000, rs4149056 is associated with PD, Metabolism/PK outcomes for atorvastatin, simvastatin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "contradicted", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC9957000 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMCID PMC9957000 reports quantitative statistics for this claim. Specifically, it provides odds ratios (OR) and confidence intervals (CI) for the association between the SLCO1B1 c.521T>C genotype (rs4149056) and changes in statin therapy, including atorvastatin and simvastatin. For example, the paper reports an adjusted OR of 0.42 (95% CI: 0.15\u20131.16) for dose change in simvastatin users with the TC/CC genotype compared to the TT genotype, and an adjusted OR of 1.97 (95% CI: 0.43\u20139.04) for atorvastatin users. However, these statistics indicate no significant association.", "correct": false}]}
{"chain_id": "chain_000025", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4519434", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4519434, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not provide direct evidence to support or contradict the claim that allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele G. The paper primarily discusses the association of the rs3778150-C allele and the rs1799971-A allele with heroin addiction, but it does not specifically compare allele A to allele G in the context of heroin dependence. Therefore, the claim is neither supported nor contradicted by the findings of this paper.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3823010 and heroin in Toxicity (PMCID PMC4519434), what confidence interval was reported?", "answer": "1.1\u20131.37", "response": "For the study of rs3823010 and heroin addiction, the reported confidence interval for the odds ratio in the Urban Health Study, African Americans was 1.02-1.37. In the Urban Health Study, European Americans, the confidence interval was 1.11-1.49. In the Australian Heroin Dependence Study, Australians of European ancestry, the confidence interval was 1.10-1.37.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000026", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4752391", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4752391, is the following pharmacogenomic claim supported or contradicted: Genotype TTA/del is associated with increased response to atenolol, hydrochlorothiazide or metoprolol in people with Hypertension as compared to genotype TTA/TTA. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs201279313 and atenolol, hydrochlorothiazide, metoprolol in Disease:Hypertension (PMCID PMC4752391), what p-value was reported for this association?", "answer": "= 1.10E-07", "response": "The p-value reported for the association of rs201279313 with blood pressure response to atenolol, hydrochlorothiazide, and metoprolol in hypertensive individuals was 2.5*10^-8 in the 3-group meta-analysis.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000027", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC12032684", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC12032684, is the following pharmacogenomic claim supported or contradicted: Genotypes CC + CT is associated with increased likelihood of statin-related myopathy when treated with atorvastatin in people with Cardiovascular Disease, Diabetes Mellitus, Acute coronary syndrome or Dyslipidaemia as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs4149056 and atorvastatin in Other:Cardiovascular Disease, Other:Diabetes Mellitus, Other:Acute coronary syndrome, Other:Dyslipidaemia (PMCID PMC12032684), what OR was reported?", "answer": "2.202", "response": "The reported odds ratio (OR) for the association of the *SLCO1B1* rs4149056 variant with statin-associated muscle symptoms (SAMS) among atorvastatin users was 2.202.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000028", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC11050844", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11050844, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased likelihood of primary graft failure or Kidney Tubular Necrosis, Acute when treated with mycophenolic acid and tacrolimus in people with Kidney Transplantation as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs717620 and mycophenolic acid, tacrolimus in Other:Kidney Transplantation (PMCID PMC11050844), what p-value was reported for this association?", "answer": "= 0.038", "response": "The p-value reported for the association of rs717620 (ABCC2 -24C>T) with mycophenolic acid and tacrolimus in kidney transplantation was 0.038.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000029", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC8673616", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC8673616, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs10485058 and methadone in Other:Opioid-Related Disorders (PMCID PMC8673616)?", "answer": 1165, "response": "The study included 1,165 cases in the analysis of rs10485058 and methadone dose in individuals with Opioid-Related Disorders.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000030", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC8291172", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC8291172, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with decreased likelihood of Hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3786362 and capecitabine in Other:Colorectal Neoplasms (PMCID PMC8291172), what OR was reported?", "answer": "0.38", "response": "The reported odds ratio (OR) for rs3786362 in relation to capecitabine-induced hand-foot syndrome in colorectal neoplasms was 0.38 (95% CI, 0.21 to 0.70).", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000031", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5721751", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5721751, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs35123024 and atenolol, hydrochlorothiazide in Disease:Hypertension (PMCID PMC5721751), what OR was reported?", "answer": "3.71", "response": "The odds ratio (OR) reported for rs35123024 in association with uncontrolled blood pressure on combination therapy with atenolol and hydrochlorothiazide was 3.71, with a 95% confidence interval of 2.13\u20136.45.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000032", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC5558540", "num_turns": 2, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5558540, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC5558540, rs4141964 is associated with Toxicity outcomes for morphine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "The claim is contradicted. The paper reports that rs4141964 is not significantly associated with clinical respiratory depression or postoperative vomiting, which are considered toxicity outcomes for morphine.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC5558540 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMCID PMC5558540 reports quantitative statistics for rs4141964 in relation to toxicity outcomes. The paper provides a p-value of 0.1767 for postoperative vomiting and a p-value of 0.2519 for clinical respiratory depression, indicating no significant association with these outcomes.", "correct": false}]}
{"chain_id": "chain_000033", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC10193607", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC10193607, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with increased likelihood of transplant rejection when treated with tacrolimus in children with Kidney Transplantation as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1045642 and tacrolimus in Other:Kidney Transplantation (PMCID PMC10193607), what p-value was reported for this association?", "answer": "= 0.01", "response": "The p-value reported for the association of rs1045642 (C3435T) with tacrolimus in kidney transplantation was 0.01 for the C allele when comparing the acute rejection group to the non-acute rejection group.", "correct": true}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "True.", "correct": false}]}
{"chain_id": "chain_000034", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC3164878", "num_turns": 2, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3164878, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC3164878, rs671531 is associated with Toxicity outcomes for fentanyl. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC3164878 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC3164878 does not report any quantitative statistic for the claim regarding rs671531 and toxicity outcomes for fentanyl.", "correct": true}]}
{"chain_id": "chain_000035", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3749570", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3749570, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with response to cyclophosphamide in people with Prostatic Neoplasms as compared to genotypes CG + GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2010963 and cyclophosphamide in Disease:Prostatic Neoplasms (PMCID PMC3749570), what p-value was reported for this association?", "answer": "= 0.0485", "response": "The reported p-value for the association between rs2010963 (\u2212634G/C) and response to cyclophosphamide in prostatic neoplasms was 0.0485.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000036", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC4660479", "num_turns": 2, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4660479, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC4660479, rs4149087 is associated with Toxicity outcomes for enalapril. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC4660479 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC4660479 does not report any quantitative statistic for the claim regarding rs4149087 and toxicity outcomes for enalapril.", "correct": true}]}
{"chain_id": "chain_000037", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC8426351", "num_turns": 2, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC8426351, is the following pharmacogenomic claim supported, contradicted, or not reported: Genotypes CT + TT is associated with decreased concentrations of rivaroxaban in men as compared to genotype CC. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "The claim is not reported in the paper. The study focuses on the pharmacokinetics of teneligliptin in relation to FMO3 and CYP3A4 polymorphisms, not on rivaroxaban or its associated genotypes.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC8426351 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC8426351 does not report any quantitative statistic such as a p-value, odds ratio (OR), or confidence interval (CI) for the claim regarding genotypes CT + TT and decreased concentrations of rivaroxaban. The paper focuses on teneligliptin and its pharmacokinetics in relation to FMO3 and CYP3A4 polymorphisms.", "correct": true}]}
{"chain_id": "chain_000038", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5488790", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5488790, is the following pharmacogenomic claim supported or contradicted: UGT1A1 *6 + *28 is not associated with increased likelihood of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms or Lung Neoplasms as compared to UGT1A1 *1/*1. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of UGT1A1*1, UGT1A1*6, UGT1A1*28 and irinotecan in Other:Colorectal Neoplasms, Other:Lung Neoplasms (PMCID PMC5488790), what p-value was reported for this association?", "answer": "= 0.7", "response": "The study reported that there were no significant differences in the incidence of severe neutropenia in patients with UGT1A1 gene polymorphisms, including UGT1A1*6 and UGT1A1*28, when compared to the wild-type genotype. The specific p-values for neutropenia in colorectal and lung cancer patients were not significant, as indicated in Table 4 and Table 5, but exact p-values for neutropenia were not explicitly stated in the text for these specific comparisons.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000039", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC3232196", "num_turns": 2, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3232196, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC3232196, rs1045642 is associated with Toxicity, Metabolism/PK outcomes for buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine, tramadol. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "The claim is not_reported. The paper (PMCID PMC3232196) does not discuss rs1045642 in relation to buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine, or tramadol. The focus of the paper is on the association of rs1045642 with drug-induced liver injury in the context of efavirenz-based antiretroviral therapy and rifampicin-based anti-tubercular therapy in TB-HIV co-infected patients.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC3232196 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC3232196 does not report any quantitative statistic (p-value, odds ratio, or confidence interval) for the claim regarding rs1045642 in relation to buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine, or tramadol. The paper focuses on the association of rs1045642 with drug-induced liver injury in the context of efavirenz and rifampicin therapy.", "correct": true}]}
{"chain_id": "chain_000040", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2072824", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2072824, is the following pharmacogenomic claim supported or contradicted: HLA-B *44:02 + *44:03 is associated with increased risk of Drug Hypersensitivity when exposed to trichloroethylene. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "Supported. The paper reports that the HLA-B*44 alleles, including *B*4402 and *B*4403, were present in 6.2% of patients with TCE-induced hypersensitivity dermatitis but were absent in TCE-tolerant workers, suggesting an association with increased risk of hypersensitivity when exposed to trichloroethylene.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of HLA-B*44:02, HLA-B*44:03 and trichloroethylene in Toxicity (PMCID PMC2072824)?", "answer": 113, "response": "There were 113 cases included in the study of HLA-B*44:02, HLA-B*44:03, and trichloroethylene-induced hypersensitivity dermatitis.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000041", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC7156285", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC7156285, is the following pharmacogenomic claim supported or contradicted: HLA-A *31:01 is associated with increased risk of drug-induced liver injury when treated with carbamazepine. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of HLA-A*31:01 and carbamazepine in Toxicity (PMCID PMC7156285), what confidence interval was reported?", "answer": "2.47\u201323.67", "response": "The confidence interval reported for the association of HLA-A*31:01 with carbamazepine-induced drug-induced liver injury (DILI) was 95% CI 2.47\u201323.67.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000042", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC12098310", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC12098310, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT is associated with decreased likelihood of Progression-free survival and overall survival when treated with doxorubicin in people with Hepatocellular Carcinoma as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3787728 and doxorubicin in Other:Hepatocellular Carcinoma (PMCID PMC12098310), what p-value was reported for this association?", "answer": "= 0.045", "response": "The p-value reported for the association of rs3787728 with overall survival (OS) was 0.04, and for progression-free survival (PFS), it was 0.054.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000043", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC11062152", "num_turns": 2, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11062152, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC11062152, UGT1A1*1, UGT1A1*6, UGT1A1*28 is associated with Dosage, Efficacy outcomes for fluorouracil, irinotecan, leucovorin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "supported", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC11062152 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMCID PMC11062152 reports p-values related to the association of UGT1A1*6 or *28 genotypes with dosage and adverse events during treatment with nanoliposomal irinotecan plus 5-fluorouracil and L-leucovorin. Specifically, the paper mentions p-values for the association of the UGT1A1*6 or *28 (+/+) genotype with decreased white blood cell count (p=0.009) and decreased neutrophil count (p=0.017). Additionally, it reports a p-value of 0.011 for the difference in initial nal-IRI doses among different UGT1A1 genotype groups.", "correct": false}]}
{"chain_id": "chain_000044", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC12308240", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC12308240, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased likelihood of Cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not provide specific information about an \"Allele A\" or \"Allele C\" in relation to increased likelihood of cardiotoxicity when treated with daunorubicin or doxorubicin in children with neoplasms. The paper discusses various genetic variants associated with anthracycline-induced cardiotoxicity, but it does not mention these specific alleles. Therefore, based on the information provided in the paper, the claim is neither supported nor contradicted. However, since the question requires a definitive answer, I would say: contradicted.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents clinical_association evidence.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs17583889 and daunorubicin, doxorubicin in Other:Neoplasms (PMCID PMC12308240), what OR was reported?", "answer": "1.84", "response": "For the study of rs17583889, the reported odds ratio (OR) for its association with anthracycline-induced cardiotoxicity, specifically daunorubicin and doxorubicin in neoplasms, was 1.84 with a 95% confidence interval of 1.34\u20132.52.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000045", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4519434", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4519434, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Heroin Dependence due to heroin as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs511435 and heroin in Toxicity (PMCID PMC4519434), what OR was reported?", "answer": "1.2", "response": "The reported odds ratio (OR) for rs511435 in association with heroin addiction was 1.10 (95% CI: 0.97-1.23) in African Americans and 1.25 (95% CI: 1.09-1.43) in European Americans. The meta-analysis OR was 1.16 (95% CI: 1.05-1.29).", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True.", "correct": false}]}
{"chain_id": "chain_000046", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC6773496", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC6773496, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs1801253 and atenolol, metoprolol in Other:Tachycardia (PMCID PMC6773496)?", "answer": 459, "response": "The study does not specify the number of cases specifically for rs1801253 and atenolol, metoprolol in individuals with Tachycardia. The study includes participants from the PEAR, PEAR-2, and INVEST trials, but it does not break down the number of cases by specific conditions such as Tachycardia.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000047", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2042718", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2042718, is the following pharmacogenomic claim supported or contradicted: CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*17. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2D6*1, CYP2D6*2, CYP2D6*17 and debrisoquine in Metabolism/PK (PMCID PMC2042718), what p-value was reported for this association?", "answer": "< 0.001", "response": "The paper does not explicitly report a p-value for the association between CYP2D6*17 and debrisoquine metabolism.", "correct": false}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": true, "response": "The paper does not provide a specific p-value for the association, so it is not possible to determine if the association would remain significant at alpha = 0.01. Therefore, the answer is false.", "correct": false}]}
{"chain_id": "chain_000048", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5354739", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5354739, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased concentrations of methotrexate in children with as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The paper does not provide evidence that allele C is associated with increased concentrations of methotrexate compared to allele T. Instead, it discusses various SNPs and their associations with methotrexate pharmacokinetics and toxicity, but does not specifically support the claim regarding allele C and T in this context.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs9282564 and methotrexate in Metabolism/PK (PMCID PMC5354739)?", "answer": 59, "response": "The study included 59 patients in the analysis of rs9282564 and methotrexate metabolism/pharmacokinetics.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True", "correct": true}]}
{"chain_id": "chain_000049", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC11758033", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11758033, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs121918623 and antiepileptics in Other:Epilepsy (PMCID PMC11758033), what p-value was reported for this association?", "answer": "= 1", "response": "The p-value reported for the association between rs121918623 and antiepileptics in epilepsy was 1.00.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000050", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3636716", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3636716, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased likelihood of drug-induced liver injury when treated with Antiinflammatory agents, non-steroids in people with drug-induced liver injury as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs9376256 and Antiinflammatory agents, non-steroids in Disease:Drug-induced liver injury (PMCID PMC3636716), what p-value was reported for this association?", "answer": "= 6.7E-8", "response": "The p-value reported for the association of rs9376256 with Antiinflammatory agents, non-steroids in drug-induced liver injury was 6.7 \u00d7 10^\u22128.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000051", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4547828", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4547828, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with likelihood of Musculoskeletal pain, Arthritis or Pain when treated with anastrozole or letrozole in women with Breast Neoplasms as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs4941131 and anastrozole, letrozole in Disease:Breast Neoplasms (PMCID PMC4547828), what confidence interval was reported?", "answer": "0.727\u20131.302", "response": "The confidence interval reported for rs4941131 in the study was 0.727\u20131.302.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000052", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC4067047", "num_turns": 2, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4067047, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC4067047, CYP4F2*1, CYP4F2*3 is associated with Efficacy outcomes for warfarin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC4067047 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC4067047 does not report any quantitative statistic for the claim regarding CYP4F2*1, CYP4F2*3 and efficacy outcomes for warfarin. The paper focuses on the association between these genetic variants and major bleeding risk, not efficacy outcomes.", "correct": true}]}
{"chain_id": "chain_000053", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC10154044", "num_turns": 2, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC10154044, is the following pharmacogenomic claim supported, contradicted, or not reported: Allele A is not associated with clearance of azathioprine in people with HIV Infections as compared to allele G. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC10154044 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC10154044 does not report any quantitative statistic for the claim regarding the association of allele A with the clearance of azathioprine in people with HIV infections.", "correct": true}]}
{"chain_id": "chain_000054", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC3554749", "num_turns": 2, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3554749, is the following pharmacogenomic claim supported, contradicted, or not reported: Genotype CC is associated with increased risk of prostate cancer-specific mortality when treated with abiraterone in men with Prostatic Neoplasms as compared to genotypes CG + GG. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC3554749 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC3554749 does not report any quantitative statistic for the claim regarding the association of genotype CC with increased risk of prostate cancer-specific mortality when treated with abiraterone. The study focuses on androgen-deprivation therapy, not abiraterone.", "correct": true}]}
{"chain_id": "chain_000055", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC8182957", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC8182957, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT are associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs7858836 and fentanyl in Other:Pain, Postoperative (PMCID PMC8182957), what p-value was reported for this association?", "answer": "= 0.0098", "response": "The p-value reported for the association between rs7858836 and fentanyl use in postoperative pain was .0017 for patients who underwent laparoscopic colectomy and .0098 for patients who underwent mandibular sagittal split ramus osteotomy.", "correct": false}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000056", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3286178", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3286178, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs11064477 and Bisphosphonates in Toxicity (PMCID PMC3286178), what p-value was reported for this association?", "answer": "= 5.16E-7", "response": "The study does not report a p-value for the association of rs11064477 with bisphosphonates in toxicity. The paper primarily focuses on rs17024608 in the RBMS3 gene.", "correct": false}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": true, "response": "The association of rs11064477 with bisphosphonates in toxicity is not reported in the paper, so it is not possible to determine its significance at alpha = 0.01. Therefore, the answer is false.", "correct": false}]}
{"chain_id": "chain_000057", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3080643", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3080643, is the following pharmacogenomic claim supported or contradicted: CYP2C9 *1/*13 is associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of CYP2C9*1, CYP2C9*13 and meloxicam in PD, Metabolism/PK (PMCID PMC3080643)?", "answer": 21, "response": "The study included 21 cases, with 12 subjects having the CYP2C9*1/*1 genotype and 9 subjects having the CYP2C9*1/*13 genotype.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000058", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC11328459", "num_turns": 2, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11328459, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC11328459, CYP2C19 poor metabolizer is associated with Efficacy, Other outcomes for aspirin, clopidogrel, Proton pump inhibitors. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "supported", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC11328459 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMCID PMC11328459 reports a hazard ratio (HR) and confidence interval (CI) for the association between CYP2C19 poor metabolizers and the risk of major adverse cardiac and cerebrovascular events (MACCE) when using proton pump inhibitors. The HR is 3.22 with a 95% CI of 1.18\u20138.78, and the p-value is 0.02.", "correct": false}]}
{"chain_id": "chain_000059", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2386778", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2386778, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased response to ethanol as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The paper reports that having at least one minor allele for certain SNPs, including those with allele T, is associated with a more intense response to alcohol.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs553202 and ethanol in Efficacy (PMCID PMC2386778), what p-value was reported for this association?", "answer": "= 0.001", "response": "The p-value reported for the association between rs553202 and ethanol in efficacy was 0.001.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000060", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4519434", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4519434, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs9384169 and heroin in Toxicity (PMCID PMC4519434)?", "answer": 1976, "response": "The study included 4,287 cases for the association of rs9384169 with heroin addiction.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000061", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5425333", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5425333, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs272893 and metformin in Disease:Diabetes Mellitus, Type 2 (PMCID PMC5425333), what p-value was reported for this association?", "answer": "= 0.57", "response": "The p-value reported for the association of rs272893 with metformin response in Diabetes Mellitus, Type 2 was 0.624.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000062", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2667987", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2667987, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with increased risk of current smoking. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The paper reports that SNP rs4423615, which has the minor allele G, is associated with current smoking (CS) with a p-value of 6.8 \u00d7 10^\u22125^, indicating an increased risk of current smoking associated with this allele.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs9424490 (PMCID PMC2667987)?", "answer": 3497, "response": "The study of rs9424490, which is associated with current smoking, included 1060 cases.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000063", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC3492352", "num_turns": 2, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3492352, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC3492352, rs12210856 is associated with Other outcomes for fentanyl. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "contradicted", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC3492352 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMCID PMC3492352 reports quantitative statistics for rs12210856. The p-value for the association of rs12210856 with fentanyl-induced emesis is 0.46, indicating no significant association.", "correct": false}]}
{"chain_id": "chain_000064", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC11732454", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11732454, is the following pharmacogenomic claim supported or contradicted: HLA-B *15:02 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with carbamazepine, lamotrigine or phenytoin. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The paper identifies HLA-B*15:02 as being significantly associated with an increased risk of Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) when treated with antiepileptic drugs, including carbamazepine and phenytoin.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of HLA-B*15:02 and carbamazepine, lamotrigine, phenytoin in Toxicity (PMCID PMC11732454)?", "answer": 90, "response": "The study included 90 tolerant controls.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000065", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC7497848", "num_turns": 2, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC7497848, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC7497848, rs316019 is associated with Dosage, Metabolism/PK outcomes for tipiracil hydrochloride, trifluridine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC7497848 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC7497848 does not report any quantitative statistic (p-value/OR/CI) for the claim regarding rs316019's association with dosage, metabolism/PK outcomes for tipiracil hydrochloride, trifluridine.", "correct": true}]}
{"chain_id": "chain_000066", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4006820", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4006820, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not provide information about an allele C being associated with increased risk of ototoxicity when treated with cisplatin in children with neoplasms as compared to allele T. The study focuses on specific genetic variants in TPMT, ABCC3, and COMT, but does not mention an allele C in this context. Therefore, the claim is neither supported nor contradicted by the paper.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs1142345 and cisplatin in Disease:Neoplasms (PMCID PMC4006820)?", "answer": 193, "response": "The study included 193 cases in the combined cohort for the analysis of rs1142345 and cisplatin in the context of neoplasms.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000067", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3093079", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3093079, is the following pharmacogenomic claim supported or contradicted: CYP2D6 *10/*10 + *1/*10 is associated with increased concentrations of n-desmethyltamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of CYP2D6*1, CYP2D6*10 and N-desmethyltamoxifen in Disease:Breast Neoplasms (PMCID PMC3093079)?", "answer": 53, "response": "The study included 165 Asian breast cancer patients. However, the specific number of cases for each CYP2D6 genotype (*1/*1, *1/*10, and *10/*10) in relation to N-desmethyltamoxifen concentrations is not explicitly stated in the provided text. The total number of patients with genotypic data for CYP2D6 polymorphisms is 111, as indicated in Table 2.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000068", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3716812", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3716812, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with risk of musculoskeletal pain when exposed to anastrozole and letrozole in women with early stage breast cancer as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The paper found that the A allele of rs9340799 was associated with a higher risk of AIs-related musculoskeletal adverse events, while the G allele was associated with a lower risk. Therefore, allele G is not associated with an increased risk compared to allele A.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs3020445 and anastrozole, letrozole in Other:with early stage breast cancer (PMCID PMC3716812)?", "answer": 230, "response": "The study included 230 controls for the analysis of rs3020445 in relation to anastrozole and letrozole in women with early-stage breast cancer.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000069", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3909953", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3909953, is the following pharmacogenomic claim supported or contradicted: CYP2D6 *3/*4 + *3/*5 + *4/*4 + *4/*5 (assigned as poor metabolizer phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) . Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5 and tamoxifen in Disease:Breast Neoplasms (PMCID PMC3909953), what p-value was reported for this association?", "answer": "= 0.02", "response": "The p-value reported for the association between CYP2D6 poor metabolizer phenotype and increased risk of recurrence when treated with tamoxifen, compared to extensive metabolizers, was 0.02.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000070", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC9613789", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC9613789, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with increased risk of dermatologic toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs10958704 and sorafenib in Other:Renal Cell Carcinoma (PMCID PMC9613789), what p-value was reported for this association?", "answer": "= 0.0091", "response": "The p-value reported for the association of rs10958704 with sorafenib-induced dermatologic toxicity in Renal Cell Carcinoma was 0.0091.", "correct": true}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000071", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC3202555", "num_turns": 2, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3202555, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC3202555, rs8192789 is associated with Efficacy, Toxicity, Other outcomes for nicotine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC3202555 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC3202555 does not report any quantitative statistic (p-value/OR/CI) for the claim regarding rs8192789.", "correct": true}]}
{"chain_id": "chain_000072", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC5806861", "num_turns": 2, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5806861, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC5806861, rs2965667 is associated with Dosage, Metabolism/PK outcomes for aspirin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC5806861 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC5806861 does not report any quantitative statistic (p-value/OR/CI) for the claim regarding rs2965667 and its association with dosage, metabolism/PK outcomes for aspirin.", "correct": true}]}
{"chain_id": "chain_000073", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4012613", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4012613, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not provide specific information about an \"Allele A\" or \"Allele C\" in relation to DPYD activity. Therefore, based on the information provided in PMCID PMC4012613, the claim cannot be directly evaluated as supported or contradicted. The paper discusses various DPYD variants and their effects on enzyme activity, but without specific reference to \"Allele A\" or \"Allele C,\" a determination cannot be made.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "functional_assay", "response": "functional_assay", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1801268 and fluorouracil in Metabolism/PK (PMCID PMC4012613), what p-value was reported for this association?", "answer": "= 6.9E-5", "response": "The study reported a p-value of 0.025 for the association of the M166V variant (rs1801268) with increased dihydropyrimidine dehydrogenase (DPD) enzyme activity when assayed with fluorouracil.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True", "correct": true}]}
{"chain_id": "chain_000074", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5611711", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5611711, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with response to furosemide in healthy individuals as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs11942223 and furosemide in Efficacy (PMCID PMC5611711), what p-value was reported for this association?", "answer": "= 0.44", "response": "The p-value reported for the association between rs11942223 and furosemide in efficacy was p\u22650.23.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000075", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC11435314", "num_turns": 2, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11435314, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC11435314, rs4148328 is associated with Metabolism/PK outcomes for fesoterodine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC11435314 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC11435314 does not report any quantitative statistic for the claim regarding rs4148328.", "correct": true}]}
{"chain_id": "chain_000076", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3567337", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3567337, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs4149056 and methotrexate in Disease:Acute lymphoblastic leukemia (PMCID PMC3567337)?", "answer": 1978, "response": "The study included 1,279 cases in the analysis of rs4149056 and methotrexate clearance in patients with acute lymphoblastic leukemia.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000077", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC6448146", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC6448146, is the following pharmacogenomic claim supported or contradicted: CYP3A7 *1C is associated with decreased steady-state concentration of etonogestrel in women as compared to CYP3A7 *1A/*1A. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "Supported.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP3A7*1A, CYP3A7*1C and etonogestrel in Efficacy, Metabolism/PK (PMCID PMC6448146), what p-value was reported for this association?", "answer": "= 0.025", "response": "The p-value reported for the association between CYP3A7*1C and etonogestrel concentrations was 0.025.", "correct": true}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000078", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC7995603", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC7995603, is the following pharmacogenomic claim supported or contradicted: CYP2D6 poor metabolizer is associated with increased likelihood of adverse events when treated with risperidone in children as compared to CYP2D6 normal metabolizer. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2D6 poor metabolizer and risperidone in Toxicity (PMCID PMC7995603), what confidence interval was reported?", "answer": "1.1\u20135.1", "response": "The confidence interval reported for the association between CYP2D6 poor/intermediate metabolizers and risperidone adverse events was 95% CI 1.1\u20135.5.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000079", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC6298606", "num_turns": 2, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC6298606, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC6298606, rs79419059 is associated with Dosage, Efficacy, Toxicity outcomes for Platinum compounds. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC6298606 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMCID PMC6298606 reports a p-value and an odds ratio with a confidence interval for the association of rs79419059 with platinum resistance. The p-value is 0.0457, the odds ratio is 4.519, and the 95% confidence interval is 1.317\u201315.501.", "correct": false}]}
{"chain_id": "chain_000080", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC7202258", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC7202258, is the following pharmacogenomic claim supported or contradicted: Genotypes AA + AG is associated with decreased risk of pain crisis in women with Anemia, Sickle Cell as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs876493 and Other:Sickle Cell Anemia (PMCID PMC7202258), what confidence interval was reported?", "answer": "0.53\u20132.28", "response": "For the study of rs876493 and Sickle Cell Anemia, the confidence interval reported for the dominant model (GG vs GA + AA) in females was 0.38\u20130.82.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the RR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True.", "correct": false}]}
{"chain_id": "chain_000081", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5700347", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5700347, is the following pharmacogenomic claim supported or contradicted: CYP2C19 ultrarapid metabolizer is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 normal metabolizer. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of CYP2C19 ultrarapid metabolizer and voriconazole in Disease:Fungal infectious disease (PMCID PMC5700347)?", "answer": 75, "response": "The study included 14 cases of CYP2C19 ultrarapid metabolizers.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "False.", "correct": false}]}
{"chain_id": "chain_000082", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC6586010", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC6586010, is the following pharmacogenomic claim supported or contradicted: CYP3A5 poor metabolizer is associated with decreased concentrations of maraviroc in people with HIV Infections as compared to CYP3A5 normal metabolizer. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP3A5 poor metabolizers and maraviroc in Disease:HIV infectious disease (PMCID PMC6586010), what p-value was reported for this association?", "answer": "= 0.343", "response": "The p-value reported for the association between CYP3A5 poor metabolizers and maraviroc concentrations in the overall population was 0.0476.", "correct": false}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000083", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5469860", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5469860, is the following pharmacogenomic claim supported or contradicted: Genotype GG is associated with increased response to propofol as compared to genotypes AA + AG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The paper reports that carriers of the homozygous major allele (GG) for the GABAA1 receptor (SNP rs2279020) were more susceptible to propofol anesthesia, as indicated by significantly lower BIS values compared to those with either heterozygous (AG) or homozygous for the minor allele (AA).", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2279020 and propofol in Other (PMCID PMC5469860), what p-value was reported for this association?", "answer": "= 0.047", "response": "The p-value reported for the association between rs2279020 in GABAA1 and propofol susceptibility, as indicated by BIS values, was 0.047.", "correct": true}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False.", "correct": true}]}
{"chain_id": "chain_000084", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC1376943", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC1376943, is the following pharmacogenomic claim supported or contradicted: Genotype CT is associated with sensitivity to caffeine or halothane in muscle. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The paper discusses the correlation between RYR1 mutations and the in vitro contracture-test data, showing a good correlation between caffeine threshold and tension values, indicating that certain genotypes, including those with the identified mutations, are associated with sensitivity to caffeine. However, no correlation was observed with halothane threshold and tension values.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "functional_assay", "response": "Functional_assay.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs118192175 and caffeine, halothane in Other (PMCID PMC1376943), what p-value was reported for this association?", "answer": "= 0.01", "response": "The paper does not provide a specific p-value for the association of rs118192175 with caffeine or halothane sensitivity. The study discusses correlations and associations in a broader context without specifying p-values for individual SNPs like rs118192175.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "False. Since the paper does not provide a specific p-value for the association of rs118192175 with caffeine or halothane sensitivity, we cannot determine statistical significance at alpha = 0.05.", "correct": false}]}
{"chain_id": "chain_000085", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC11732454", "num_turns": 2, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11732454, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC11732454, HLA-A*33:03 is associated with Toxicity outcomes for carbamazepine, lamotrigine, phenytoin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC11732454 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC11732454 does not report any quantitative statistic (p-value/OR/CI) for the claim regarding HLA-A*33:03 and its association with toxicity outcomes for carbamazepine, lamotrigine, or phenytoin.", "correct": true}]}
{"chain_id": "chain_000086", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4006820", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4006820, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs12201199 and cisplatin in Disease:Neoplasms (PMCID PMC4006820)?", "answer": 106, "response": "The study included 193 cases in the combined cohort for the analysis of rs12201199 and cisplatin in Disease: Neoplasms.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000087", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3710533", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3710533, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs8060157 and raloxifene, tamoxifen in Disease:Breast Neoplasms (PMCID PMC3710533), what confidence interval was reported?", "answer": "0.6\u20130.81", "response": "The confidence interval reported for rs8060157 in the context of raloxifene and tamoxifen therapy for breast neoplasms was 0.6 to 0.81.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000088", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5908896", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5908896, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with severity of gastrointestinal toxicity when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs4657437 and fluorouracil, irinotecan, leucovorin in Disease:Colorectal Neoplasms (PMCID PMC5908896), what OR was reported?", "answer": "2.54", "response": "The reported odds ratio (OR) for rs4657437 in the context of gastrointestinal toxicity when treated with fluorouracil, irinotecan, and leucovorin in colorectal neoplasms was 0.48 (95% CI: 0.24\u20130.99) in the discovery cohort.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True.", "correct": false}]}
{"chain_id": "chain_000089", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4492197", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4492197, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Hypersensitivity when treated with asparaginase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs6021191 and asparaginase in Disease:Acute lymphoblastic leukemia (PMCID PMC4492197)?", "answer": 3308, "response": "A total of 589 cases of asparaginase hypersensitivity were included in the study.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000090", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC4956330", "num_turns": 2, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4956330, is the following pharmacogenomic claim supported, contradicted, or not reported: CYP2C9 *2 is associated with dose of flurbiprofen in children with Heart Diseases as compared to CYP2C9 *1. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC4956330 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC4956330 does not report any quantitative statistic (p-value/OR/CI) for this claim.", "correct": true}]}
{"chain_id": "chain_000091", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC3235084", "num_turns": 2, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3235084, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC3235084, rs4974081 is associated with Metabolism/PK outcomes for mycophenolate mofetil. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "contradicted", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC3235084 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMCID PMC3235084 reports a quantitative statistic for the claim regarding rs4974081. The odds ratio (OR) for biopsy-proven acute rejection (BPAR) was 0.66 with a 95% confidence interval (CI) of [0.39\u20131.13] and a p-value of 0.13 for rs4974081 variant allele carriers, indicating no significant association.", "correct": false}]}
{"chain_id": "chain_000092", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC4206576", "num_turns": 2, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4206576, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC4206576, rs940052 is associated with Dosage, Toxicity outcomes for radiotherapy. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Supported.", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC4206576 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMCID PMC4206576 reports quantitative statistics for the association of rs940052 with toxicity outcomes. Specifically, for esophagitis, the odds ratio (OR) in the meta-analysis is 0.34 with a 95% confidence interval (CI) of 0.19\u20130.62, and a p-value of 4.03\u00d710^\u22124.", "correct": false}]}
{"chain_id": "chain_000093", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC5944577", "num_turns": 2, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5944577, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC5944577, CYP3A5 poor metabolizer and intermediate metabolizer genotypes is associated with Efficacy, Other, Metabolism/PK outcomes for N-desmethyltamoxifen. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "contradicted", "correct": false}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC5944577 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMCID PMC5944577 reports a p-value for the association between CYP3A5 and N-desmethyltamoxifen plasma concentrations, which is 0.9713, indicating no significant association.", "correct": false}]}
{"chain_id": "chain_000094", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC11538333", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11538333, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Neoplasms as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs79802223 and vincristine in Other:Neoplasms (PMCID PMC11538333)?", "answer": 550, "response": "550 cases were included in the study of rs79802223 and vincristine in Other:Neoplasms.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000095", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3570048", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3570048, is the following pharmacogenomic claim supported or contradicted: Genotype TT is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CC + CT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The paper reports that African\u2013American patients homozygous for the lower EPHX1 activity allele (TT) demonstrated a lower CBZ-diol:CBZ-E ratio at 2 hours compared to patients with at least one C (His) allele, indicating decreased metabolism of carbamazepine.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs1051740 and carbamazepine in Disease:Epilepsy (PMCID PMC3570048)?", "answer": 58, "response": "The study included 90 epilepsy patients, but the specific number of cases analyzed for the rs1051740 SNP in relation to carbamazepine metabolism is not explicitly stated in the paper. The analysis was performed within the context of the overall cohort.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000096", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC12331468", "num_turns": 2, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC12331468, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC12331468, rs1695 is associated with Toxicity outcomes for mercaptopurine, methotrexate. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC12331468 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC12331468 does not report any quantitative statistic (p-value/OR/CI) for the claim regarding rs1695's association with toxicity outcomes for mercaptopurine and methotrexate.", "correct": true}]}
{"chain_id": "chain_000097", "chain_family": "B_claim\u2192presence_absence", "pmcid": "PMC11786012", "num_turns": 2, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11786012, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMC11786012, HLA-DPB1*02:02 is associated with Dosage, Metabolism/PK outcomes for pembrolizumab. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMCID PMC11786012 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMCID PMC11786012 does not report any quantitative statistic (p-value/OR/CI) for the claim regarding HLA-DPB1*02:02 being associated with Dosage, Metabolism/PK outcomes for pembrolizumab.", "correct": true}]}
{"chain_id": "chain_000098", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3124814", "num_turns": 4, "model": "gpt-4o", "all_correct": false, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3124814, is the following pharmacogenomic claim supported or contradicted: Genotypes AG + GG are associated with decreased overall survival due to carboplatin, cisplatin, docetaxel or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The paper reports that in the PT group (platinum plus taxanes, which includes carboplatin, cisplatin, docetaxel, or paclitaxel), the genotypes AG + GG of the SNP rs17661089 in the MAP3K1 gene are associated with a decreased overall survival compared to the genotype AA, with a hazard ratio of 1.38 (95% CI: 1.11\u20131.72).", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association.", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs17661089 and carboplatin, cisplatin, docetaxel, paclitaxel in Disease:Non-Small Cell Lung Carcinoma (PMCID PMC3124814), what HR was reported?", "answer": "1.25", "response": "The reported hazard ratio (HR) for the SNP rs17661089 in the MAP3K1 gene in the context of treatment with carboplatin, cisplatin, docetaxel, or paclitaxel (PT group) in non-small cell lung carcinoma is 1.38, with a 95% confidence interval of 1.11\u20131.72.", "correct": false}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the HR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
{"chain_id": "chain_000099", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5467955", "num_turns": 4, "model": "gpt-4o", "all_correct": true, "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5467955, is the following pharmacogenomic claim supported or contradicted: HLA-DRB1 *15:02 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The paper does not mention HLA-DRB1 *15:02 as being associated with the risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin. The focus is on HLA-B*15:02 and HLA-A*24:02 as risk factors for these conditions.", "correct": true}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association", "correct": true}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of HLA-DRB1*15:02 and phenytoin in Toxicity (PMCID PMC5467955)?", "answer": 40, "response": "The study included 40 controls for the investigation of phenytoin-induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.", "correct": true}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True.", "correct": true}]}
